Literature DB >> 23908468

MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice.

John D Belcher1, Mark Young, Chunsheng Chen, Julia Nguyen, Kenneth Burhop, Phuc Tran, Gregory M Vercellotti.   

Abstract

Transgenic sickle mice expressing β(S) hemoglobin have activated vascular endothelium in multiple organs that exhibits enhanced expression of NF-ĸB and adhesion molecules and promotes microvascular stasis in sickle, but not normal, mice in response to hypoxia/reoxygenation (H/R), or heme. Induction of heme oxygenase-1 (HO-1) or administration of its products, carbon monoxide (CO) or biliverdin, inhibits microvascular stasis in sickle mice. Infusion of human hemoglobin conjugated with polyethylene glycol and saturated with CO (MP4CO) markedly induced hepatic HO-1 activity and inhibited NF-ĸB activation and H/R-induced microvascular stasis in sickle mice. These effects were mediated by CO; saline or MP4 saturated with O2 (MP4OX) had little to no effect on H/R-induced stasis, though unmodified oxyhemoglobin exacerbated stasis. The HO-1 inhibitor, tin protoporphyrin, blocked MP4CO protection, consistent with HO-1 involvement in the protection afforded by MP4CO. MP4CO also induced nuclear factor-erythroid 2 p45-related factor 2 (Nrf2), an important transcriptional regulator of HO-1 and other antioxidant genes. In a heterozygous (hemoglobin-AS) sickle mouse model, intravenous hemin induced cardiovascular collapse and mortality within 120 minutes, which was significantly reduced by MP4CO, but not MP4OX. These data demonstrate that MP4CO induces cytoprotective Nrf2 and HO-1 and decreases NF-ĸB activation, microvascular stasis, and mortality in transgenic sickle mouse models.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23908468      PMCID: PMC4067504          DOI: 10.1182/blood-2013-02-486282

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  The use of carbon monoxide to prevent sickle-cell formation.

Authors:  J A SIRS
Journal:  Lancet       Date:  1963-05-04       Impact factor: 79.321

2.  Accelerated autoxidation and heme loss due to instability of sickle hemoglobin.

Authors:  R P Hebbel; W T Morgan; J W Eaton; B E Hedlund
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

3.  CO production by feces and urine.

Authors:  M D Levitt; C J Ellis; R R Engel
Journal:  J Lab Clin Med       Date:  1989-02

4.  Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice.

Authors:  S F Yet; R Tian; M D Layne; Z Y Wang; K Maemura; M Solovyeva; B Ith; L G Melo; L Zhang; J S Ingwall; V J Dzau; M E Lee; M A Perrella
Journal:  Circ Res       Date:  2001-07-20       Impact factor: 17.367

Review 5.  The social network of carbon monoxide in medicine.

Authors:  Barbara Wegiel; Douglas W Hanto; Leo E Otterbein
Journal:  Trends Mol Med       Date:  2012-11-08       Impact factor: 11.951

6.  Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart.

Authors:  Guangwu Wang; Tariq Hamid; Rachel J Keith; Guihua Zhou; Charles R Partridge; Xilin Xiang; Justin R Kingery; Robert K Lewis; Qianhong Li; D Gregg Rokosh; Rachael Ford; Francis G Spinale; Daniel W Riggs; Sanjay Srivastava; Aruni Bhatnagar; Roberto Bolli; Sumanth D Prabhu
Journal:  Circulation       Date:  2010-04-19       Impact factor: 29.690

7.  Sickle hemoglobin confers tolerance to Plasmodium infection.

Authors:  Ana Ferreira; Ivo Marguti; Ingo Bechmann; Viktória Jeney; Angelo Chora; Nuno R Palha; Sofia Rebelo; Annie Henri; Yves Beuzard; Miguel P Soares
Journal:  Cell       Date:  2011-04-29       Impact factor: 41.582

Review 8.  Redox regulation of mitochondrial biogenesis.

Authors:  Claude A Piantadosi; Hagir B Suliman
Journal:  Free Radic Biol Med       Date:  2012-09-19       Impact factor: 7.376

9.  CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats.

Authors:  K D Vandegriff; M A Young; J Lohman; A Bellelli; M Samaja; A Malavalli; R M Winslow
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 10.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

View more
  35 in total

Review 1.  Environmental determinants of severity in sickle cell disease.

Authors:  Sanjay Tewari; Valentine Brousse; Frédéric B Piel; Stephan Menzel; David C Rees
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 2.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

Authors:  Marilyn J Telen
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

3.  Macrophage metabolic adaptation to heme detoxification involves CO-dependent activation of the pentose phosphate pathway.

Authors:  Gael F P Bories; Scott Yeudall; Vlad Serbulea; Todd E Fox; Brant E Isakson; Norbert Leitinger
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

4.  Impairment of neutrophil oxidative burst in children with sickle cell disease is associated with heme oxygenase-1.

Authors:  Ceri Evans; Katharine Orf; Erzsebet Horvath; Michael Levin; Josu De La Fuente; Subarna Chakravorty; Aubrey J Cunnington
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

5.  HO-1 and CO: fighters vs sickle cell disease?

Authors:  Jesus A Araujo
Journal:  Blood       Date:  2013-10-10       Impact factor: 22.113

6.  Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Ping Zhang; Fuad Abdulla; Phong Nguyen; Trevor Killeen; Pauline Xu; Gerry O'Sullivan; Karl A Nath; Gregory M Vercellotti
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

7.  Critical role of C5a in sickle cell disease.

Authors:  Gregory M Vercellotti; Agustin P Dalmasso; Terry R Schaid; Julia Nguyen; Chunsheng Chen; Marna E Ericson; Fuad Abdulla; Trevor Killeen; Margaret A Lindorfer; Ronald P Taylor; John D Belcher
Journal:  Am J Hematol       Date:  2019-01-03       Impact factor: 10.047

Review 8.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

Review 9.  Danger signals from mitochondrial DAMPS in trauma and post-injury sepsis.

Authors:  C J Hauser; L E Otterbein
Journal:  Eur J Trauma Emerg Surg       Date:  2018-05-24       Impact factor: 3.693

Review 10.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.